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Abstract
Background:  The side effects and burden of anticoagulant treatments may contribute to poor
compliance and consequently to treatment failure. A specific questionnaire is necessary to assess patients'
needs and their perceptions of anticoagulant treatment.
Methods: A conceptual model of expectation and satisfaction with anticoagulant treatment was designed
by an advisory board and used to guide patient (n = 31) and clinician (n = 17) interviews in French, US
English and Dutch. Patients had either atrial fibrillation (AF), deep venous thrombosis (DVT), or pulmonary
embolism (PE). Following interviews, three PACT-Q language versions were developed simultaneously and
further pilot-tested by 19 patients. Linguistic validations were performed for additional language versions.
Results: Initial concepts were developed to cover three areas of interest: 'Treatment', 'Disease and
Complications' and 'Information about disease and anticoagulant treatment'. After clinician and patient
interviews, concepts were further refined into four domains and 17 concepts; test versions of the PACT-
Q were then created simultaneously in three languages, each containing 27 items grouped into four
domains: "Treatment Expectations" (7 items), "Convenience" (11 items), "Burden of Disease and
Treatment" (2 items) and "Anticoagulant Treatment Satisfaction" (7 items). No item was deleted or added
after pilot testing as patients found the PACT-Q easy to understand and appropriate in length in all
languages. The PACT-Q was divided into two parts: the first part to measure the expectations and the
second to measure the convenience, burden and treatment satisfaction, for evaluation prior to and after
anticoagulant treatment, respectively. Eleven additional language versions were linguistically validated.
Conclusion: The PACT-Q has been rigorously developed and linguistically validated. It is available in 14
languages for use with thromboembolic patients, including AF, PE and DVT patients. Its validation and
psychometric properties have been tested and are presented in a separate manuscript.
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Background
Thromboembolic events are a major cause of mortality
and morbidity in Western societies [1-3]. Such events
occur when a mechanical mass, termed thrombus,
obstructs vascular blood flow locally or detaches and clots
to occlude blood flow downstream. Thromboembolic
events or recurrences thereof can be effectively reduced by
the use of anticoagulants. Currently, three conditions con-
stitute the majority of indications for long-term anticoag-
ulant treatment: atrial fibrillation (AF), where
anticoagulants are used to prevent stroke, and deep
venous thrombosis (DVT) and pulmonary embolism
(PE), where anticoagulants are used to prevent recurrent
disease.
Standard long-term anticoagulant treatment consists of
oral vitamin K antagonists (VKA) including warfarin,
phenprocoumon and acenocoumarol. However, there are
well-known drawbacks in the routine medical use of VKA.
For example, all must be given daily and have interactions
with food and a many commonly used drugs, which is a
problem since many patients requiring anticoagulant
therapy are elderly. Moreover, VKA potencies vary
between patients, resulting in unpredictable pharmacody-
namic effects and requiring regular monitoring. Signifi-
cant side effects can also occur, which are most
prominently bleeding disorders.
As a result, these drawbacks are likely to impose a signifi-
cant burden on patients (e.g. complicated and frequent
monitoring, side effects) and probably affect their health-
related quality of life (HRQoL). In fact, most patients eli-
gible to receive VKA do not receive optimal treatment.
Instead, they receive less effective doses or no therapy at
all [4-9].
Intense research is currently underway in an effort to
develop safer and more effective anticoagulants. Some of
these have the advantage of an increased half-life, allow-
ing for once-a-week administration [10]. Others have the
potential to be given orally, without laboratory monitor-
ing [11,12]. For assessing the real value of new drugs in
this field, the evaluation of patients' perspectives and sat-
isfaction towards these treatments will be necessary. Tra-
ditional efficacy endpoints alone may not be able to
include all the benefits of novel therapies such as the
reduction in treatment burden.
With the help of patient-reported outcome (PRO) ques-
tionnaires, including treatment satisfaction question-
naires, treatment benefits for the patient are now often
evaluated in clinical trials [13,14]. Treatment satisfaction
is a concept that is distinct from other PROs as it focuses
on the patients' rating of salient aspects of a treatment
experience. These ratings are determined by comparisons
with the patients' subjective standards, formed by expec-
tations, past experiences, personality characteristics, val-
ues and beliefs [15-17]. Failure to achieve sufficient
treatment satisfaction has been reported to cause poor
treatment compliance [18-20], which in turn may dimin-
ish the effectiveness of treatments – especially among
patients with chronic conditions [21,22].
In order to evaluate the full benefits of anticoagulant treat-
ments, a specific patient-reported questionnaire that
assesses patients' satisfaction with anticoagulant treat-
ment is thus required. Ideally, this questionnaire must be
applicable to a wide range of patients receiving anticoag-
ulant therapies and must also address issues related to
treatment attributes such as the route of administration
(e.g. subcutaneous versus oral). In addition, this question-
naire should achieve currently recommended validation
standards and be available in several languages for use in
multinational clinical trials.
A literature search led to the conclusion that no question-
naire meeting all these requirements exists for evaluating
anticoagulant treatments [7,23-30]. Therefore, we devel-
oped and validated a patient-reported treatment satisfac-
tion questionnaire, the 'Perception of Anticoagulant
Treatment Questionnaire' (PACT-Q), in several languages,
using a wide spectrum of thromboembolic patients and
following currently recommended methodology.
Methods
Participants
Advisory Board
An advisory board consisting of 8 experts from a diverse
range of disciplines, was set up to provide expert input on
all stages of development for the questionnaire and to
work with a team of questionnaire specialists. Their input
consisted in creating a conceptual model, making choices
to optimize the questionnaire development process, vali-
dating the results at each critical step of development and
providing final decisions on subsequent procedures.
Clinician and patient recruitment
Clinicians were recruited among specialists in DVT, PE
and/or AF, from France, the Netherlands and the US.
Patients were recruited in France, the Netherlands and the
US, either by the specialists who were interviewed or by
specialists from our network. In order to complete the tar-
geted sample, three patients were recruited via an advertis-
ing campaign on a thrombosis website in the
Netherlands, and five were recruited via an agency special-
ised in patient recruitment in the US. They had to be over
18 years-old, have had a thromboembolic event within
the last two years, or AF for at least three months prior to
the interview. Patients also had to have taken an anticoag-Health and Quality of Life Outcomes 2009, 7:9 http://www.hqlo.com/content/7/1/9
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ulant within the three months prior to the interview, be
willing and able to participate in a one-hour interview and
speak the local language fluently. They were asked to pro-
vide a written consent regarding their participation in the
study. Patients with psychotic or psychiatric diseases,
newly diagnosed serious chronic conditions other than
AF, or a rating of 4 or 5 on the Rankin Scale were excluded
from the study. To ensure a broad spectrum of patients,
the population was to include one AF patient who was
still at work per country, half of all DVT/PE patients had
to be aged 50 or below, and patients had to have different
levels of education for all disease conditions.
Concept development
The advisory board first met to generate an initial list of
concepts related to the expectations and satisfaction of
patients with anticoagulant treatment. The concept list
was created in English and was based on the patients'
main concerns found in a literature review and subse-
quently completed with the collective experience of the
individual advisory board members. This concept list pro-
vided the structure for designing the clinician interview
guide.
The objectives of the guide were to 1) capture clinicians'
personal experience in the fields of DVT, PE and/or AF, 2)
collect their opinions on the current state of disease man-
agement and treatments, 3) document the improvements
that were needed in the treatment and management of
these disorders and 4) discuss their impressions of the
patients' experience and concerns regarding their disor-
ders and treatments. The final guide was developed in UK
English, then validated by the advisory board and trans-
lated into US English, Dutch and French.
Concepts can be general or highly specific; in the text, we
use the term "detailed concepts" at the more specific level,
which can be assessed with a specific item in the question-
naire; detailed concepts that are closely related are
grouped in "concepts", and concepts that are expected to
be pooled to calculate a score are further grouped in a
"domain".
Clinician interviews
Trained researchers from the native language of the inter-
viewees conducted all interviews. Interviews were per-
formed to amend and complete a list of concepts defined
during the first advisory board meeting and to enable the
writing of a guide for patient interviews. Clinician inter-
views were conducted over the phone, recorded and tran-
scribed into grids. Transcripts were analysed in each
country and were used to amend and complete the initial
list of concepts. Concepts within this second list were cat-
egorised into new global concepts and detailed concepts
sections. Results from each country were consolidated to
create an international list.
From this list, a patient guide was designed for the patient
interviews. The objectives of the guide were to 1) collect
patients' opinions and perspectives on the management
and treatment of their disease in their own words, 2) iden-
tify the important aspects of their treatment and disease
management, 3) identify how patients assess the efficacy
and safety of their anticoagulant treatment and their pref-
erences, 4) identify advantages and constraints related to
anticoagulant treatment as perceived by patients and 5)
identify patients' worries and expectations concerning
anticoagulant treatment and medical follow-up. The final
guide, developed in UK English, was also validated by the
advisory board and translated into US English, Dutch and
French.
Patient interviews
Patient interviews were performed to test the list of con-
cepts and to collect patient responses in their own word-
ing to create the items of the questionnaire. A target goal
of 30 patient interviews (ten per country) was set prior to
recruiting patients. In each country, three patients with
DVT, three patients with PE and four patients with AF
were to be recruited to provide a relevant spectrum of
patients. All the research processes were conducted fol-
lowing the tenets of the Declaration of Helsinki.
Interviews were recorded and transcribed into a grid. Ver-
batim transcripts were analysed by clinical condition, in
each language, and used to amend and complete the inter-
national list of concepts. All global and detailed concepts
were then translated into English and used to create the
questionnaire items.
Item generation
Items were generated simultaneously in Dutch, French
and US English during a three-day 'item generation meet-
ing' with questionnaire specialists. Briefly, relevant verba-
tim responses were first selected from patient transcripts,
analysed and organised into a list of concepts then further
grouped into domains. A short list of detailed concepts
was selected. Following review and validation of the short
list by the advisory board, items were drafted to provide
the first version of the questionnaire. The advisory board
then validated the first US English, Dutch and French ver-
sion of the questionnaire.
Content validity testing
Native speaking interviewers conducted content validity
interviews. The goal was to assess the ease of comprehen-
sion, clarity, cultural equivalence, preference and appro-
priateness of the first version of the PACT-Q (instructions,
questionnaire items and response scales). Interviews wereHealth and Quality of Life Outcomes 2009, 7:9 http://www.hqlo.com/content/7/1/9
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performed with patients other than those who partici-
pated in the concept development phase, but recruited
following the same criteria; one extra criterion was added,
consisting in the inclusion of one DVT and one PE patient
currently receiving or having received subcutaneous injec-
tion of anticoagulant treatment during the two months
prior to the interview.
A patient interview guide was developed in UK English
and translated into Dutch, US English and French. Inter-
views with patients with prior DVT, PE and AF were per-
formed face-to-face at home, over the phone, or at
hospital and transcribed into grids. Relevant comments
were all translated into English. If required, they were
reformulated in both English and the target language to
make them clearer and easier to understand. The pilot ver-
sion of the questionnaire was then produced and vali-
dated by the advisory board.
Linguistic validation
An internationally acknowledged translation methodol-
ogy was used in order to obtain eleven additional lan-
guage versions that were conceptually equivalent and
easily understandable by each of the target population
[31,32]. For seven of the languages (Czech, Danish, Cana-
dian French, German, Italian, Polish and US Spanish),
translation followed a standard linguistic validation proc-
ess, which included a conceptual analysis of the original
instrument, the recruitment and briefing of a consultant
in each target country, a forward translation step, a back-
ward translation step, a pilot-testing step (clinician
reviewing and cognitive debriefing with five patients in
each target country) and two final proof-readings (one by
clinicians and one by patients). For the four remaining
languages (Belgian Dutch, Australian English, Canadian
English, and Belgian French), that were closely similar to
previously validated language versions (e.g. Dutch/Bel-
gian Dutch), an adjusted validation process was per-
formed. The adjusted validation included all the standard
validation procedures with the exception of the forward
and backward translations that were replaced by a lan-
guage adaptation step.
Results
Participant characteristics
Description of the clinicians
A total of 17 clinicians were interviewed: France (n = 6),
the Netherlands (n = 6) and the US (n = 5). Clinicians
were cardiologists, internists, respirologists and vascular
medicine specialists, with extensive experience (from 4 to
37 years) with DVT, PE and AF patients. The mean
number of DVT and PE patients treated per year by clini-
cians was 189 and the mean number of AF patients treated
per year was 129. Interviews were one-hour long on aver-
age.
Description of the patients
The socio-demographic characteristics of the interviewed
patients are provided according to disease condition in
Tables 1 and 2. Thirty-one patients, 14 males and 17
females, were interviewed for all three countries. Nine
patients were diagnosed with DVT, 9 with PE and 13 with
AF (Table 2). The interviewed population was heterogene-
ous in terms of age, employment status, treatment experi-
ence and perspective towards anticoagulant treatment.
For example, among the 31 patients interviewed, eleven
were actively working or homemakers, 16 were retired,
one was unemployed, one was disabled and two were
unable to work due to their health status (Table 1). The
mean patient age was 57 years; on average AF patients
were older than patients with DVT or PE (69 versus 47 and
51 years respectively). Anticoagulant treatment experience
was also longer in AF patients than in DVT and PE patients
(respective mean duration of 5.6, 1.2 and 2.3 years).
Concept development
Based on the advisory board deliberation, concepts were
initially grouped into three areas of interest: 1) Treatment,
2) Disease and Complications and 3) Information about
disease and anticoagulant treatment. After clinician and
patient interviews, they were further refined into a list of
seventeen concepts, each of which is detailed hereafter:
Convenience related to treatment
Five issues of concern related to treatment convenience
were discussed: using tablets, receiving injections, per-
forming self-injections, requiring long-term treatment
and effects on daily activities. Tablets were seen as rapid
and easy to use, carry and swallow. However, timings,
dose complexity, dose variability and compliance when
traveling were major constraints. For injections, some
patients reported being not bothered by or afraid of the
procedure. However, injections were also seen as unpleas-
ant, painful, limiting on travel and time, a source of anxi-
ety and fear, associated with allergies and subject to dose
variability. Some patients expressed a willingness to per-
form self-injections, preferring the independence and the
fact that regular blood tests are not required. Others spoke
of fear and difficulties in performing the injection, obtain-
ing the products, transporting the equipment and prob-
lems associated with age. A few patients felt that they
would become used to long-term treatment but required
regularity and organization. Daily activities that were
reported to be affected by treatment included changes in
sports, leisure, travel, work, gardening and the amount of
injuries incurred.
Convenience related to blood monitoring
Some patients and clinicians reported that regular blood
tests could interfere with daily life and work and repre-
sented a constant reminder of their disease condition. TheHealth and Quality of Life Outcomes 2009, 7:9 http://www.hqlo.com/content/7/1/9
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frequency of tests, social stigma, compliance, costs, trans-
port requirements, time spent waiting and pain associated
with the tests were also issues. Advantages included feel-
ings of confidence and reassurance and a means for check-
ing treatment efficacy.
Perceived efficacy
Issues of concern included relief of symptoms, confidence
in the treatment and protection against future throm-
boembolic events. Some patients felt more confident with
injections than oral treatment. Other patients preferred
oral treatment and some reported no perception of treat-
ment efficacy.
Perceived safety – Side effects
Some patients and clinicians suggested that no concerns
were apparent regarding side effects, treatment interac-
tions or food interactions. However, local bruises, dis-
comfort and gum bleeding, social and physical stigmas,
allergies, hair loss and memory loss were sometimes
reported as important side effects. Fears associated with
bleeding and negative interactions with other treatments
were also a concern. A few patients expressed that the need
to be more cautious with food choice, alternative treat-
ments and physical activity were constraining.
Patient preference on the type of administration route
Patients' preferences varied and included preferences for
oral treatment, self-injection and injection by a third
party.
Autonomy
Some patients perceived an improvement in their auton-
omy, whereas others did not yet report a gain. Some
patients reported better autonomy with oral treatment
and self-injection than injections performed by a third
Table 1: Patient socio-demographic characteristics according to disease condition
DVT
(n = 9)
PE
(n = 9)
AF
(n = 13)
Total
(n = 31)
COUNTRY (n)
France 3 3 5 11
The Netherlands 3 3 4 10
The United States 3 3 4 10
GENDER (n)
Male 5 2 7 14
Female 4 7 6 17
AGE (years)
Range 21 – 77 30 – 74 39 – 79 21 – 79
Mean 47.4 51.3 68.5 57.4
LIVING SITUATION (n)
Living alone 3 . 5 8
Living as a couple 6 9 8 23
LEVEL OF EDUCATION (n)
Primary school 1 . 3 4
High school diploma 3 3 3 9
Some college or vocational school 1 3 4 8
College or university degree 3 2 1 6
Graduate or professional school 1 1 1 3
Other, please specify . . 1 (grammar school) 1
EMPLOYMENT STATUS (n)
Full-time paid employment 4 1 1 6
Part-time paid employment 1* 1* 1 3
Homemaker/housewife . 1 1 2
Retired 3 3 10 16
Unemployed . 1 . 1
Not working due to present health status . 2 . 2
Other, please specify 1 (disabled) . . 1
* part-time because partly unable to work due to health status
AF, atrial fibrillation; DVT, deep venous thrombosis; PE, pulmonary embolismHealth and Quality of Life Outcomes 2009, 7:9 http://www.hqlo.com/content/7/1/9
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party. However, other patients expressed that blood tests
and clinician follow-up lower anxiety and provide a sense
of confidence. Feelings of dependency on the treatment
were noted. The importance of compliance was some-
times expressed by both clinicians and patients. Several
patients felt that compliance and monitoring were better
with injections, and easier when not performed at home.
Compliance was also seen as being related to age, the fre-
quency of treatment intakes and the amount of side effects
experienced.
Medical follow-up
Issues of concern included feelings of confidence and sat-
isfaction with medical staff availability, reassurance and
care received. Performing blood tests and good communi-
cation were important for feelings of confidence. Follow-
up visits were sometimes seen as a constraint.
Information provided to patients by clinicians (clinicians' point of 
view)
As described by clinicians, information included explana-
tions on the disease and its origin, treatment require-
ments, mode of action and side effects, as well as
information on blood tests, emergency procedures and
interactions with food. A few clinicians stated that the
level of information was low, particularly with regard to
vital prognoses and that comprehension was also low for
older patients.
Table 2: Initial interviews: patient clinical characteristics according to disease condition
DVT
(n = 9)
PE
(n = 9)
AF
(n = 13)
Total
(n = 31)
DISEASE INFORMATION: Duration of AF or last PE/DVT (years)
Range 0.3 – 2.6 0.6 – 3 0.4 – 13 0.3 – 13
Mean 1.3 1.2 5.8 3.1
TREATMENT INFORMATION
Name(s) of anticoagulation treatment(s)
Previscan 11 35
Coumadine 55 61 6
Fenprocoumon . . 1 1
Fraxodi .1 .1
Sintrom .. 11
Marcoumar 21 25
Acenocoumarol 1 1 . 2
Current anticoagulant administration route
Oral 98 1 3 3 0
Injection .1 .1
Experience of anticoagulant self-injections
Yes 33 28
No 66 1 1 2 3
Blood test frequency
Every 1 – 2 weeks 5 5 3 13
Every 2 – 4 weeks 2 2 3 7
Every month 22 48
Every 1–2 months . . 3 3
Receiving an anticoagulant treatment since (year)
Range 0.3 – 2 0.6 – 8 0.5 – 13 0.3 – 13
Mean 1.2 2.3 5.6 3.3
Duration of anticoagulant treatment
Lifetime 25 1 2 1 9
One year .2 .2
6 months 31 15
Less than 6 months 1 1 . 2
Unknown 2. . 2
Finished 1. . 1
OTHER CO-MORBIDITIES
Yes 45 81 7
No 54 51 4
AF, atrial fibrillation; DVT, deep venous thrombosis; PE, pulmonary embolismHealth and Quality of Life Outcomes 2009, 7:9 http://www.hqlo.com/content/7/1/9
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Information provided to patients by clinicians (patients' point of view)
As described by patients, information was similar to what
clinicians described. However, some patients specified
that more information was needed regarding disease
background, sequelae, conditions of treatment use, dura-
tion of use, side effects, emergency procedures, food and
other treatment complications. Some patients were con-
cerned with understanding the variance in blood rates and
forgetting the information provided. Some patients pre-
ferred to have information while others did not.
Patients' expectations
Expectations included being cured, symptom relief, pre-
vention of future events, having no complications or side
effects, a decrease in health risk and treatment efficacy.
Some patients expected short-term treatments and limited
duration of disease, others expected not to have immedi-
ate results. Some patients expected having injections, that
the treatment would be easy-to-use and that they would
have medical support and follow-ups. Some patients had
no specific expectations.
Wishes
Some patients' desires included having information on
the disease risk and origin, on treatment and its interac-
tions with food and other treatments, and seeing blood
test results. Patients' opinions varied with regard to
whether they wanted blood tests or not. Some patients
requested symptom relief, a simplified regular dosage, a
once a week injection and more exposure to medical staff.
Worries and anxiety
These feelings were reported by some patients to be
related to the disease (heredity, chronology, complica-
tions, symptoms), the treatment (side effects, drug inter-
actions, hospital visits, injections, blood test results,
forgetting the treatment), stopping the treatment (fear of
relapse), mortality, or changes that might occur in work,
the future and during pregnancy.
Perception of disease and symptoms
A few patients were concerned with issues related to the
disease and symptoms, including swelling in the leg and
arm, stiffness of the leg, pain in the leg, chest, arm and
back, shortness of breath, dyspnea, heart palpitations,
nausea, vomiting, vertigo, dizziness, headache, fatigue,
tiredness, coughing, choking (blood in particular),
metabolism problems, heavy perspiration, high choles-
terol, bad feelings, cold fingertips and toes, and fever.
Symptom alleviation
According to patients, symptom alleviation could include
treatment, rest, appropriate clothing, proper positioning
and cold water.
Impact of disease on physical activities
For some patients, physical impact included limitations in
activities such as walking, sports, going out, vacationing
and gardening. Patients also reported avoidance of some
movements and shortness of breath.
Psychological impact of the disease on patients
Patients sometimes described the disease as affecting their
mood and general awareness.
Impact of disease on daily life
Such impact included effects on the patients' sleep, aes-
thetic appearance, dealing with local stigmas, lower
energy levels, wearing compression stockings and changes
in daily activities to avoid injuries and becoming too tired.
Concepts were organised into a list of four domains
("Treatment Expectations", "Convenience", "Anticoagu-
lant Treatment Satisfaction" and "Burden of Disease and
Treatment"), and then prioritised according to their rele-
vance in assessing treatment satisfaction and convenience
as well as on their ability to distinguish between different
types of treatment (Table 3). Thirty detailed concepts cor-
responding to the previous described concepts were estab-
lished, each being evaluated for validity across countries
and disease conditions. One detailed concept on cost and
one on the overall satisfaction with anticoagulant treat-
ment were included in the short list. In contrast, no items
were developed for the concept 'information about dis-
ease and anticoagulant treatment' as this concept was con-
sidered unessential to treatment assessment.
Item generation
Using the detailed concepts listed and based on patients'
verbatim transcripts, three language versions (French,
Dutch and US English) of the pilot questionnaire were
created and validated, each containing 27 culturally
equivalent items grouped into four domains: "Treatment
Expectations" (7 items), "Convenience" (11 items), "Bur-
den of Disease and Treatment" (2 items) and "Anticoagu-
lant Treatment Satisfaction" (7 items) (Figure 1). No item
was created for the detailed concepts about 'recovery',
'constraints (frequency of blood monitoring)', 'safe
administration (mistakes in administration)', 'route of
administration', and one single item was created for the
concept 'impact of side effects, disease symptoms and
blood monitoring on work and daily activities' since these
detailed concepts were either covered elsewhere or quali-
fied as a source of misunderstanding. Answers were
designed according to 5-point Likert response scales. The
questionnaire format was subsequently divided into two
parts: the first part to measure expectations (7 items), to
be administered before receiving treatment, and the sec-
ond to measure convenience, burden and treatment satis-Health and Quality of Life Outcomes 2009, 7:9 http://www.hqlo.com/content/7/1/9
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Table 3: Short list of concept classification provided from patient interviews
Domains Concepts Detailed concepts Matching item in final PACT-
Q
Treatment Expectations Efficacy Reassurance; occurrence or 
recurrence of events
#A1
Alleviation of symptoms (e.g. pain) #A2
Recovery None
Safety Safe administration 
(mistakes in administration)
#A5
Minimisation of side effects 
(bruising, bleeding)
#A3
Convenience Easy administration/route #A4
Autonomy Keeping control 
(of schedule, disease, treatment)
# A6
Cost Cost #A7
Convenience (evaluation) Treatment Administration/route #B1
Bothersomeness, constraints #B2
Dose adaptation #B3
Drug-drug interactions #B4
Drug-food interactions #B5
Flexibility 
(storage, handling, place, context)
#B6
Time 
(planning, time spent, transport)
#B7
Blood test procedure Constraints 
(frequency of monitoring)
None
Time (planning, time spent, 
transport); trip
#B8
Bothersomeness, constraints #B9
Autonomy Dependence on nurse, caregiver #B10
Anticoagulant Treatment 
Satisfaction (evaluation)
Efficacy Reassurance, occurrence, or 
reoccurrence of events
#D1
Alleviation of disease symptoms #D2
Safety Side effects #D3
Safe administration 
(mistakes in administration)
NoneHealth and Quality of Life Outcomes 2009, 7:9 http://www.hqlo.com/content/7/1/9
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faction (20 items), to be administered after having
received the treatment.
Content validity testing
Description of patients
Nineteen patients were recruited in France, the Nether-
lands and the US, seven with DVT (the Netherlands, n = 2;
US, n = 2; France, n = 3), five with PE (the Netherlands, n
= 1; US, n = 2; France, n = 2), six with AF (n = 2 in each
country). One patient who had not had a thromboem-
bolic event but who had an increased risk of thrombosis
due to major abdominal vein surgery was included due to
prior experience with self-injection. Patients' socio-demo-
graphic and clinical characteristics were similar to those
interviewed for the concept development. Among the 19
patients interviewed, nine were males, ten were active,
seven were retired, one was a housewife, and one was not
working due to present health status. The mean age of
patients was 52.3 years, the mean disease duration was 2.8
years. All patients were receiving anticoagulant treatment.
Three patients out of 19 were receiving injections of anti-
coagulants and seven patients had had an experience with
self-injection of anticoagulants. Twelve patients were to
receive a lifetime treatment.
Patients' comments
In the three countries, patients found the questionnaire
clear and easy to understand in general. They found the
length appropriate and the layout was well accepted.
Patients gave specific minor comments on each item of
the questionnaire that were incorporated. These corre-
sponded to re-wording or to adding more detail to the
questions to make them more accurate. No item was
deleted or added after pilot testing. Final wording of the
questionnaire was decided and validated by the advisory
board. The questionnaire was named the PACT-Q (Per-
ception of Anticoagulant Treatment Questionnaire). The
first part was labeled PACT-Q1, and aimed at measuring
expectations. The second part was labeled PACT-Q2 and
aimed at measuring convenience, burden of disease and
treatment, and anticoagulant treatment satisfaction.
Linguistic validation
Linguistic validation was performed on the PACT-Q into
eleven additional languages (Australian English, Belgian
Dutch, Belgian French, Canadian English, Canadian
French, Czech, Danish, German, Italian, Polish and US
Spanish) to obtain conceptual equivalence between the
target language versions and the original questionnaire.
Conceptual and linguistic issues
As sometimes no direct word equivalent exists in a target
language (either linguistically or culturally), an appropri-
ate translation was put forward, discussed with the devel-
oper and implemented in the translations when they were
found acceptable. The aim was to retain options consid-
ered simple, colloquial and conceptually equivalent to the
original. For example, "bother" as a verb could encompass
a range of feelings on the part of the respondent. In the
languages where this alternative was possible, it was con-
sidered preferable to use an equivalent of "to bother"
instead of an equivalent of "to annoy/to worry", as these
convey a slightly different meaning. In the languages,
when more idiomatic, possible alternatives used for "how
bothered are you by... " were similar to" how much are
you preoccupied by", "do you feel it is a burden to" or
"how inconvenient is it for you". Overall, terminological
Autonomy Route of administration None
Keeping control of disease/worries 
about not keeping control
#D4
Satisfaction with staff #D5
Preference with treatment form #D6
Overall treatment satisfaction #D7
Burden of Disease & 
Treatment (evaluation)
Impact of side effects, disease 
symptoms and blood monitoring
On daily activities #C1
On work #C1
Discomfort Because of bruising, pain #C2
Treatment interruption Worries about interrupting 
treatment
#B11
Table 3: Short list of concept classification provided from patient interviews (Continued)Health and Quality of Life Outcomes 2009, 7:9 http://www.hqlo.com/content/7/1/9
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differences did not have an impact on the interpretation
of the question.
Other examples of conceptual or linguistic issues were as
follows: in some cases, the equivalent in the different lan-
guages of "dependent on others" was confused with a con-
cept of addiction or of embarrassment. In addition, it was
felt a little degrading, as though it were a crippling disease,
psychologically speaking. The equivalent of "to have more
need of others' help" was therefore used, as being more
understandable and culturally acceptable.
In some languages, the "follow-up" concept was difficult
to express. "Follow-up" of treatment included assessing
the status of the disease. In addition, the word used to
render "follow-up" referred to subsequent examinations,
e.g. visits to the doctor (for check-ups). It referred to the
patient and not really to the disease. Literal equivalents of
"follow-up" also appeared to be technical terms used by
clinicians rather than patients, who viewed them as being
complementary to the medicine used in their treatment.
In languages for which "follow-up" proved a difficult term
to translate or understand, alternative expressions such as
"monitoring" were found acceptable.
Pilot testing
In each country, the respective PACT-Q version was tested
on five patients with either DVT, PE or AF and following
an anticoagulant treatment. The mean age of the respond-
ents was 57 years across countries, ranging from 47 to 64
years. Out of the 55 respondents interviewed, 27 were
men. Respondents took an average of 12 minutes to com-
plete the questionnaire (ranging from 5 to 20 minutes
across countries).
Overall, the questionnaire was found to be clear, relevant
and appropriate to the circumstances. The examples pro-
vided were perceived as very helpful and the questions
were therefore well understood. Some respondents found
the questionnaire to be complete and short. Others had
minor comments including redundancy or similarity for
some questions.
The items relating to interaction of other drugs and food
with the anticoagulant treatment caused a certain level of
worry and anxiety. However, the difficulties expressed by
respondents did not concern the wording of the question
but rather the desire for more explanations or informa-
tion. In the "Convenience" domain, the question "How
worried are you about having to interrupt or stop your
anticoagulant treatment?" seemed to confuse certain
Refined conceptual model of the PACT-Q pilot version Figure 1
Refined conceptual model of the PACT-Q pilot version.Health and Quality of Life Outcomes 2009, 7:9 http://www.hqlo.com/content/7/1/9
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respondents, because the possibility of having to interrupt
or stop their treatment had not occurred to them before
the question suggested it. Respondents could not imagine
why they would stop treatment unless they had recovered
from their illness.
After further analysis of their comments, it appeared that
the respondents understood the question, but that as they
had never considered the question, it raised many new
questions for them. Thus, the items were kept. Please note
here that the items with their specific wording are availa-
ble on request from the authors.
Discussion
Numerous studies have shown the relationship between
patients' satisfaction and treatment compliance, which
may lead to treatment failure [20-22,33]. Reported out-
comes on patients' satisfaction are therefore of interest
when one wants to measure treatment benefits, to under-
stand the needs and expectations of patients and to
explain treatment compliance. Satisfaction "instruments"
can provide direct comparison of treatment administra-
tion routes and procedures; they present succinct evalua-
tions of patients' perceptions through the use of a short set
of simple questions; they offer additional relevant infor-
mation that cannot be assessed through clinical end-
points; they can be applied to clinical studies with fixed
timelines.
Previous attempts at measuring satisfaction with anticoag-
ulant treatment have been published [7,23-26,29]. In a
few cases, patient satisfaction questionnaires were devel-
oped with a focus on the structures and processes of anti-
coagulant medical care. Although some information can
be derived from the medical care-satisfaction literature,
studies are often too broadly focused to be of value in the
assessment of satisfaction with specific regimens or thera-
pies, which is particularly noticeable when questionnaires
attempt to measure both satisfaction and HRQoL in one
instrument [34]. Indeed, while the conceptual model
underlying satisfaction suggests that it should be meas-
ured against expectations [35], HRQoL is by definition
related to a specific condition or disease and is a multidi-
mensional construct requiring the measurement of physi-
cal functioning, mental functioning, social functioning
and emotional well-being [36,37].
The PACT-Q was developed as a specific treatment satis-
faction instrument for thromboembolic patients with
anticoagulant treatment.
Development of PACT-Q
The development of the PACT-Q followed a rigorous
qualitative, international multi-step approach, involving
a literature review, simultaneous patient and clinician
interviews in three languages, advisory board validations,
pilot-testing of the preliminary instrument in the same
three countries and linguistic validation into eleven lan-
guage versions. Patient and clinician interviews identified
a range of views regarding the nature and management of
treatment and of disease. Comprehensive review of all
decision processes and materials by experts, questionnaire
specialists and linguists at each appropriate stage of the
development process ensured the thorough development
and validation of the questionnaire and allowed for its
immediate linguistic adaptations. The resulting PACT-Q is
a brief, easy-to-use, high quality patient-completed ques-
tionnaire, available in 14 different languages.
Number of interviews necessary to ensure the relevance 
and comprehensiveness of the instrument
The rationale for setting the number of interviews in qual-
itative research should in theory be based on the concept
of saturation [38]. Roughly, saturation is achieved when
additional interviews no longer add new concepts to the
list. However, in our simultaneous development design,
the evidence of the comprehensiveness of the identified
concepts was the concordance in findings from the three
different countries, rather than the concordance between
consecutive sets of interviews in one single country.
Multinational applicability of PACT-Q
A well-identified limitation to generalisability of PRO
instruments is due to the cross-cultural differences. The
PACT-Q was developed simultaneously in multiple lan-
guages, i.e. French, US English and Dutch, and underwent
rigorous linguistic validation. This reduces the risk of sys-
tematic measurement error at the item level (i.e. item
bias) and ensures the consistency of concepts across dif-
ferent cultures. The procedure was intended to yield 'opti-
mal' measures for adaptation into different cultures.
Additionally, it aimed to produce a measure that was less
susceptible to cultural differences than a questionnaire
developed only in one language and followed by transla-
tion into other languages [39].
Linguistic validation of the PACT-Q into Australian Eng-
lish, Belgian Dutch, Belgian French, Canadian English,
Canadian French, Czech, Danish, German, Italian, Polish
and US Spanish was established according to a rigorous
development and translation process to ensure concep-
tual equivalence and cultural relevance across all lan-
guages [31,32]. To achieve this, a comprehensive review
of the concept short list and the conceptual definitions of
the original items was carried out. To ensure understand-
ing of the underlying concepts of the PACT-Q, and hence
conceptual equivalence across all countries, the list of
concepts was systematically compared across all coun-
tries. Such conceptual transparency adheres to the current
guidelines on thorough questionnaire development andHealth and Quality of Life Outcomes 2009, 7:9 http://www.hqlo.com/content/7/1/9
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linguistic validation, and ultimately allows for the inter-
national comparison and pooling of data to generate eas-
ily interpretable summary scores [40]. The availability of
the PACT-Q in 14 language versions makes it internation-
ally applicable.
The simultaneous development conducted in three Euro-
pean countries actually facilitated the linguistic validation
of the questionnaire in eleven other languages in western
countries. However, an assessment of cross-cultural valid-
ity will be a necessary step in regions where the experi-
ence, values and priorities of the patients may differ.
Satisfaction and expectations
The division of the PACT-Q into PACT-Q1 (expectations)
on the one hand and PACT-Q2 (convenience, burden and
treatment satisfaction) on the other hand for prior and
follow-up assessment, is expected to facilitate the interpre-
tation of the future scores. As several authors agree, satis-
faction is at least partly linked to prior expectations
[13,15]. In therapeutic trials, the assessment of expecta-
tions could be useful to 1) describe the level of expecta-
tions for several treatment attributes at baseline, and 2) be
part of multivariate models explaining the respective
impact of treatment characteristics and patients' expecta-
tions on the levels of satisfaction reported by the patients.
However, as expectations result from former experience
and information received, the contents of a questionnaire
are limited by the range of experience the patients inter-
viewed have had, as well as by the information they have
received. It is likely that changes in the disease as well as
in future new therapies (for example curative treatments)
might impact the nature and the levels of expectations as
well as those of satisfaction.
Next steps in the validation process
The heterogeneity of the target population at each stage of
the development and validation process ensured that the
relevance of the PACT-Q extends to a variety of anticoag-
ulant patients with different condition severities, socio-
demographic characteristics and treatment formulations.
As AF, DVT and PE patients account for a large proportion
of anticoagulant patients, the PACT-Q is expected to be
used for assessment of the issues of greatest concern for a
wide spectrum of patients.
The qualitative research process used to develop the
PACT-Q aims at providing researchers with an instrument
based on strong assumptions regarding its content and its
structure. However, validation is an ongoing process, and
the true worth of an instrument only becomes clear with
its use. Further quantitative psychometric validation steps
will be necessary to consolidate its validity and suitability
for application in clinical research studies.
Conclusion
As an increasing number of safer and equally effective
anticoagulant treatment alternatives become available,
satisfaction will be an important variable to assist in prod-
uct differentiation. The PACT-Q, a rigorously developed
treatment satisfaction questionnaire, is able to assess sat-
isfaction pertaining to different types of anticoagulant
treatments and is now available in 14 languages for use
with AF, PE and DVT patients. Its structure and psycho-
metric properties were validated and are presented in a
separate manuscript [Prins MH, Guillemin I, et al: Scoring
and psychometric validation of the Perception of Antico-
agulant Treatment Questionnaire (PACT-Q), Unpublished]
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